6XC1 Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Soleno Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.17 |
| 52 Week High | US$0.77 |
| 52 Week Low | US$0.16 |
| Beta | 0.24 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -77.36% |
| 33 Year Change | n/a |
| 5 Year Change | -88.30% |
| Change since IPO | -99.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6XC1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | -1.4% |
| 1Y | -77.4% | -16.2% | 11.8% |
Return vs Industry: 6XC1 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 6XC1 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 6XC1 volatility | |
|---|---|
| 6XC1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6XC1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 6XC1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 20 | Anish Bhatnagar | soleno.life |
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. Fundamentals Summary
| 6XC1 fundamental statistics | |
|---|---|
| Market cap | €22.99m |
| Earnings (TTM) | -€23.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs 6XC1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6XC1 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$23.42m |
| Earnings | -US$23.42m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6XC1 perform over the long term?
See historical performance and comparison